YUANZAN
Procurement guides2026-11-12

Brucella AST in 2026: EUCAST Breakpoints, Laboratory Quality and Consumable Sourcing

Understand EUCAST 2026 Brucella breakpoints, AST method differences, laboratory quality requirements and microbiology consumable sourcing.

Brucella AST in 2026: EUCAST Breakpoints, Laboratory Quality and Consumable Sourcing

Antimicrobial susceptibility testing (AST) provides important information for clinical microbiology and antimicrobial resistance surveillance.

For Brucella species, however, reliable susceptibility testing requires particular attention to organism-specific interpretation criteria, testing methods, quality management and laboratory biosafety.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical Breakpoint Tables, version 16.1, include a dedicated section for Brucella melitensis, with clinical breakpoints for selected antimicrobial agents.

The tables also contain bracketed breakpoints, which require additional interpretation and should not be treated in the same way as unrestricted susceptibility categories.

Recent research from the French National Reference Centre for Brucellosis further emphasizes the importance of method selection.

Published on October 27, 2026, the study examined 234 Brucella isolates and identified important discrepancies between susceptibility testing methods for streptomycin.

For microbiology laboratories, diagnostic suppliers and procurement teams, these developments highlight a wider principle:

Reliable laboratory results depend on appropriate standards, validated methods, quality controls and suitable laboratory materials—not on any single instrument or consumable.

This guide explains the scope of EUCAST 2026 guidance, the importance of method consistency, and the role of supplier qualification in microbiology laboratory purchasing.

Technical information reviewed: November 10, 2026. This article provides general educational and procurement information and does not replace official AST standards, approved laboratory procedures or clinical guidance.

1. What EUCAST 2026 Covers for Brucella melitensis

EUCAST publishes clinical breakpoint tables used to interpret antimicrobial susceptibility testing results for specified bacterial species and antimicrobial agents.

Version 16.1 is valid from June 24 through December 31, 2026.

Importantly, the official tables include dedicated Brucella melitensis entries.

This corrects a common misunderstanding that the 2026 EUCAST framework contains only epidemiological cut-off values for Brucella or lacks organism-specific clinical breakpoints.

Antimicrobial Categories Included in the Tables

The Brucella melitensis section includes selected agents from the following groups:

Antimicrobial GroupExamples Appearing in EUCAST v16.1Important Considerations
FluoroquinolonesCiprofloxacin, levofloxacinApply the relevant organism–agent criteria
AminoglycosidesGentamicin, streptomycinSome entries use bracketed breakpoints
TetracyclinesDoxycycline, tetracyclineMethod and interpretation notes remain important
Other agentsRifampicin, trimethoprim-sulfamethoxazoleReview specific footnotes and reporting requirements
Selected indication-specific agentsCeftriaxone for meningitisInterpretation is restricted to the specified indication and notes

The existence of a breakpoint does not mean that every antimicrobial agent is suitable for every clinical situation.

The relevant breakpoint, testing method, indication and EUCAST notes must be considered together.

This article does not reproduce numerical susceptibility thresholds. Laboratories should use the official EUCAST tables and associated guidance rather than rely on a secondary summary.

Breakpoints Are Version-Specific

EUCAST tables are revised over time.

The publication of version 16.1 should not be interpreted as meaning that every organism-specific breakpoint in the document was first introduced in June 2026.

The mid-year revision also included changes affecting several anaerobic bacterial species.

For Brucella, the important procurement and laboratory-management issue is understanding the applicable published criteria and maintaining the correct version of the reference documents.

2. Clinical Breakpoints, ECOFFs and Bracketed Values

Three related concepts are particularly important when interpreting antimicrobial susceptibility information.

Clinical Breakpoints

Clinical breakpoints support interpretation of susceptibility results using defined organism–antimicrobial combinations and relevant clinical considerations.

EUCAST uses three principal categories:

S — Susceptible, standard dosing regimen

The organism is categorized as susceptible under the applicable standard dosing conditions.

I — Susceptible, increased exposure

The organism is categorized as susceptible when appropriate increased antimicrobial exposure is achieved.

R — Resistant

The organism is categorized as resistant under the defined interpretation framework.

These categories should be applied only where suitable clinical breakpoints exist and the relevant interpretation requirements are met.

Epidemiological Cut-Off Values (ECOFFs)

An ECOFF distinguishes the wild-type population from isolates with acquired resistance mechanisms, based on the distribution of minimum inhibitory concentrations.

ECOFFs are useful for microbiological surveillance and identifying potential non-wild-type populations.

However, an ECOFF is not automatically interchangeable with a clinical breakpoint used for treatment-related interpretation.

What Are Bracketed Breakpoints?

EUCAST uses breakpoints in brackets for certain antimicrobial agents or applications where additional therapeutic measures may be necessary and evidence for monotherapy is generally limited.

EUCAST explains that these values are essentially ECOFF-like boundaries that distinguish populations with and without acquired resistance.

They require particular caution in interpretation.

For Brucella melitensis, the official table includes bracketed entries for certain agents.

Laboratories should therefore review the relevant EUCAST notes and bracketed-breakpoint guidance rather than treat every table entry as a straightforward stand-alone treatment recommendation.

Comparison of Interpretation Frameworks

ConceptPrimary PurposeInterpretation Limitation
Clinical breakpointCategorize susceptibility under defined clinical conditionsApplies only to the specified organism, agent and conditions
ECOFFDistinguish wild-type and non-wild-type populationsDoes not independently predict clinical treatment outcome
Bracketed breakpointProvide restricted interpretation subject to additional conditionsMust be read with EUCAST's specific guidance
Laboratory QC criterionDetermine whether analytical performance is acceptableDoes not replace clinical interpretation criteria

For laboratory management, maintaining the distinction between these concepts is essential for consistent reporting.

3. What the 2026 French National Reference Centre Study Found

On October 27, 2026, researchers from the French National Reference Centre for Brucellosis published a study in PLOS Neglected Tropical Diseases examining the application of EUCAST 2026 susceptibility criteria.

The study analyzed 234 Brucella isolates collected between January 2017 and June 2026.

Study Population

CharacteristicReported Finding
Total isolates234
Brucella melitensis210 (89.7%)
Brucella suis15 (6.4%)
Brucella abortus5 (2.1%)
Brucella amazoniensis4 (1.7%)

The collection was predominantly composed of B. melitensis.

The findings therefore provide useful evidence from a large national reference collection, but they should not automatically be generalized to every Brucella species, geographic region or testing environment.

Differences Between AST Methods

The researchers evaluated susceptibility results using routine laboratory methods.

A significant methodological issue emerged with streptomycin.

One gradient diffusion approach produced elevated minimum inhibitory concentration (MIC) results for a substantial proportion of isolates.

However, disk diffusion results from the same collection supported a different susceptibility interpretation.

This discrepancy demonstrated why laboratories should not assume that different AST methods always provide equivalent results for a particular organism–agent combination.

Implications for Laboratory Quality

The study supports several practical conclusions:

1. Laboratories should use the applicable EUCAST interpretive framework.

2. Results depend on the analytical method as well as the organism and antimicrobial agent.

3. Method-specific limitations should be considered when reviewing unexpected findings.

4. Quality assurance and documentation are important for reproducible results.

5. Resistance surveillance findings require careful interpretation before broader conclusions are drawn.

The study also reported that approximately half of the isolates had rifampicin MICs within two doubling dilutions of the relevant ECOFF, supporting continued attention to surveillance.

These findings are specific to the study population and methods.

They do not establish the performance of commercial laboratory plasticware or any particular consumable manufacturer.

Why This Research Matters for Procurement

Method consistency depends primarily on validated analytical procedures and suitable equipment.

Nevertheless, laboratories also need stable access to the materials specified by their procedures.

Procurement teams should understand when a proposed product substitution requires technical review or formal change control.

Supplier continuity, product identification and documentation therefore support the laboratory's broader quality-management process.

4. Laboratory Biosafety and Quality Management

Brucella species are associated with significant laboratory-acquired infection risk.

CDC guidance identifies brucellosis as a frequently reported laboratory-associated bacterial infection and emphasizes the importance of suitable containment and precautions.

For laboratories handling suspected Brucella materials, biosafety requirements must be established through institutional risk assessment and applicable rules.

Biosafety Is Not a Consumable Feature

A sterile tube, filter pipette tip or sealed container does not independently make work involving potentially infectious Brucella materials safe.

Similarly, ordinary laboratory product specifications cannot replace appropriate facilities, personnel training, containment equipment or approved safety procedures.

Any work involving suspected or confirmed Brucella should be performed only within the laboratory's authorized biosafety framework.

This article does not provide Brucella culture, manipulation or susceptibility-testing procedures.

Quality Management Requirements

A reliable laboratory quality system should address:

● Method documentation and document control

● Relevant instrument performance records

● Defined acceptance criteria

● Appropriate quality controls

● Product and reagent identification

● Traceability of relevant lots

● Supplier qualification

● Technical review of product substitutions

● Investigation of nonconforming results

These requirements support laboratory consistency across changing personnel, purchasing cycles and analytical workloads.

Managing Supplier Changes

An alternative product may appear equivalent based on dimensions or packaging.

However, changes in material, product geometry, cleanliness specifications or manufacturing processes may require further assessment.

Procurement teams should therefore coordinate relevant changes with laboratory quality personnel rather than approve replacements solely on the basis of commercial availability.

5. Laboratory Consumables: Selecting Products by Workflow

Microbiology laboratories use many product categories, but not all consumables play the same role.

In particular, materials used for routine molecular biology should not be confused with the specialized products and procedures required for phenotypic antimicrobial susceptibility testing.

General Laboratory Consumable Evaluation

Product CategoryPotential Supporting ApplicationMain Procurement Requirements
Pipette tipsGeneral liquid handling and sample preparationPipette compatibility, material and relevant cleanliness specifications
Microcentrifuge tubesSmall-volume laboratory handlingVolume, closure and material
Centrifuge tubesApplicable sample-processing proceduresCapacity, operating-condition compatibility and closure
PCR tubes and platesMolecular biology and nucleic acid workflowsInstrument, thermal and optical compatibility
Deep-well platesCompatible automated sample-processing systemsPlate format, working volume and platform compatibility
Storage tubesDefined laboratory storage applicationsMaterial, closure, labeling and storage requirements

These are general laboratory categories.

Their inclusion does not imply that every item is required for Brucella AST or qualified for handling infectious Brucella materials.

Molecular Testing Is Different From Phenotypic AST

PCR-based methods may support the identification or characterization of organisms and selected genetic targets.

However, detecting a genetic sequence does not automatically provide the same information as a phenotypic antimicrobial susceptibility result.

Likewise, PCR plates and tubes cannot replace the dedicated methods and materials specified for phenotypic AST.

Procurement teams should maintain clear distinctions between molecular testing and susceptibility-testing requirements.

Consumable Compatibility Checklist

Before approving a replacement product, review:

● Current reference SKU

● Intended workflow

● Equipment or platform compatibility

● Product specifications

● Required cleanliness or sterility characteristics

● Relevant documentation

● Packaging and storage

● Supplier change-management arrangements

Any necessary technical evaluation should follow the laboratory's established procedures.

6. Qualifying a Laboratory Consumables Supplier

For microbiology laboratories, diagnostic companies and distributors, supplier evaluation should include both product requirements and commercial supply conditions.

The objective is to establish reliable access to products with appropriate specifications and documentation.

Supplier Qualification Matrix

Evaluation AreaWhat Buyers Should Confirm
Product identityExact product and catalog reference
Material and dimensionsAvailable technical specifications
Intended useSuitability for the required general laboratory application
Product claimsSupporting evidence for relevant specifications
Quality managementRelevant certificate scope and validity
Lot identificationAvailable traceability information
PackagingLabeling, quantity and protection requirements
Supply continuityReorder arrangements and lead times
Change communicationHow relevant specifications or materials changes are reported
Commercial evaluationSample availability and qualification process

ISO Certification and Product-Level Evidence

An ISO-certified quality management system provides information about the supplier's management processes.

It does not automatically establish that every product meets a particular clinical diagnostic requirement.

For example, ISO 13485 certification concerns the quality management system for medical devices within the certificate's scope.

Product-specific regulatory status, intended use and performance evidence must still be evaluated separately.

Reference SKU Matching

When requesting a product alternative, distributors can provide a current supplier SKU or detailed product specification.

Useful information includes:

● Product name and type

● Reference SKU

● Dimensions or material requirements

● Packaging format

● Target market

● Estimated annual demand

● Applicable quality documentation

● OEM or private-label requirements

A supplier can use this information to identify potential matches.

The final acceptance decision remains subject to the buyer's technical and quality requirements.

7. Yuanzan General Laboratory Consumables and OEM Sourcing

Yuanzan Life Sciences supplies selected laboratory plastic consumables for routine liquid handling, sample processing, storage and molecular biology workflows.

Relevant product categories include:

Liquid Handling Products

Manual pipettes, standard pipette tips and selected filter-tip options.

Explore Yuanzan Liquid Handling

Molecular Biology Consumables

PCR tubes, PCR plates and related products.

Explore Yuanzan Molecular Biology Consumables

Sample Processing and Storage

Centrifuge tubes, microcentrifuge tubes, deep-well plates and selected storage consumables.

Explore Laboratory Consumables

Manufacturing and OEM/ODM Support

Yuanzan supports selected laboratory consumable manufacturing, OEM and private-label projects.

Depending on the product category, relevant discussions may include:

● Existing product supply

● Reference SKU matching

● Product specifications

● Packaging and labeling customization

● Commercial sample evaluation

● Manufacturing feasibility

● Quality documentation

● Repeat-order planning

Explore Yuanzan Manufacturing

Discuss OEM and Private-Label Projects

Important Scope Limitation

Yuanzan does not represent its general-purpose laboratory plasticware as specifically validated for Brucella antimicrobial susceptibility testing or infectious Brucella handling.

Product suitability for regulated diagnostic applications requires separate assessment against the applicable method, intended use and regulatory requirements.

Neither manufacturing capability nor ISO quality management certification should be interpreted as proof of organism-specific diagnostic validation.

Conclusion

EUCAST Clinical Breakpoint Tables v16.1 provide organism-specific susceptibility interpretation criteria for selected antimicrobial agents against Brucella melitensis.

However, the presence of published breakpoints does not eliminate the need for method consistency, careful interpretation, appropriate biosafety and laboratory quality management.

The 2026 French National Reference Centre study demonstrated the importance of considering method-related discrepancies, particularly in the interpretation of streptomycin susceptibility results.

For laboratory managers, maintaining current reference documents and an appropriate quality system is essential.

For procurement teams, product specifications, supplier qualification, sample evaluation and repeat supply help support laboratory operations.

Laboratory consumables should be evaluated according to their actual intended role rather than assumed to be universally suitable for specialized microbiology or diagnostic applications.

Discuss Laboratory Consumable Sourcing Requirements

Are you sourcing pipette tips, PCR consumables, sample-processing tubes or general laboratory plasticware for a microbiology laboratory or distribution business?

Provide your reference SKUs, required specifications, destination market, estimated order volume and documentation requirements.

Yuanzan can review available product information, commercial sample options and OEM/private-label project requirements.

Primary CTA: Request Consumable Samples for Supplier Evaluation

Secondary CTA: Discuss OEM and Private-Label Manufacturing

These services concern general laboratory consumable sourcing. They do not imply Brucella-specific diagnostic validation or suitability for infectious organism handling.

References

1. EUCAST — Clinical Breakpoint Tables v16.1, June 24–December 31, 2026.

2. EUCAST — Guidance on Breakpoints in Brackets.

3. Gaillard M. et al. (2026). Validation of EUCAST 2026 Breakpoints for Brucella Species Using Routine Laboratory Methods: A Comprehensive French National Reference Centre Study. PLOS Neglected Tropical Diseases, 20(10), e0014817.

4. CDC — Laboratory Risks for Brucellosis, June 2, 2026.

5. Yuanzan Life Sciences — Laboratory Consumables Product Catalog, 2026.

Technical references provide scientific and quality-management context. They do not constitute independent validation or endorsement of Yuanzan products.

FAQ

Does EUCAST v16.1 include Brucella melitensis clinical breakpoints?

Yes. The tables include a dedicated section for Brucella melitensis, with clinical breakpoints for selected antimicrobial agents. The relevant notes and restrictions must be reviewed before interpretation.

What is the difference between an ECOFF and a clinical breakpoint?

An ECOFF helps distinguish wild-type and non-wild-type populations based on MIC distributions. A clinical breakpoint supports susceptibility categorization under defined clinical conditions. They are not automatically interchangeable.

Why do bracketed breakpoints require special attention?

EUCAST uses bracketed values to indicate restrictions or additional considerations, including situations where certain agents should not be considered independently of other therapeutic measures. Laboratories should refer to the official guidance.

What did the 2026 French Brucella study report?

The researchers analyzed 234 isolates and identified important differences between laboratory methods when evaluating streptomycin susceptibility, reinforcing the need for method-specific interpretation and quality control.

Are PCR consumables equivalent to phenotypic AST consumables?

No. PCR consumables support molecular workflows. Phenotypic AST requires its own appropriately specified methods and materials.

Are Yuanzan laboratory consumables approved for Brucella AST?

Yuanzan supplies selected general laboratory consumables. The company does not represent these products as specifically validated or authorized for Brucella AST or infectious Brucella handling.

Can distributors request samples or OEM manufacturing support?

Selected laboratory plastic consumables may be available for commercial evaluation. OEM and private-label arrangements depend on the product and project requirements.

pics of lab consumables